• Chronic functional tricuspid regurgitation (FTR) with a minimum of moderate tricuspid regurgitation (2-4)

• Age≥18 and ≤85 years old

• New York Heart Association (NYHA) Class II, III or ambulatory IV

• Left ventricular ejection fraction (LVEF) ≥30%

• Undergoing cardiac surgical procedure with the planned use of cardiopulmonary bypass (surgical arm only)

• Functional tricuspid valve regurgitation pathology with a structurally normal valve; and tricuspid valve annular diameter ≥ 40 mm (or 21 mm/m2) and ≤55 mm (or 29 mm/m2) or 2-4 + FTR

• Patient provides written Informed Consent before any study-specific tests or procedures are performed

• Patient is willing and able to comply with all specified study evaluations